India  

Lantheus Holdings Announces Submission of Drug Master File for NM-01 in the U.S.

Business Wire Tuesday, 12 January 2021 ()
Lantheus Holdings Announces Submission of Drug Master File for NM-01 in the U.S.NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and products, announced that it has filed a Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA) for NM-01, a PD-L1 imaging biomarker, and will begin making the biomarker avail
0
shares
ShareTweetSavePostSend
 

You Might Like